The combination of oHSV-1 and CD70 CAR-T provides mutual enhancement of both therapies—enhancing CAR-T infiltration, activation, and survival, and “reprogramming” the tumor microenvironment from immunosuppressive to proinflammatory. The gene discussed is CD70; the disease is neoplasm.